Advertisement

Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19

      *The following joint statement from the ACC, American Heart Association and Heart Failure Society of America addresses using renin angiotensin aldosterone system (RAAS) antagonists in COVID-19. "The continued highest standard of care for cardiovascular disease patients diagnosed with COVID-19 is top priority, but there are no experimental or clinical data demonstrating beneficial or adverse outcomes among COVID-19 patients using ACE-I or ARB medications," said Richard J. Kovacs, MD, FACC. "We urge urgent, additional research that can guide us to optimal care for the millions of people worldwide with cardiovascular disease and who may contract COVID-19. These recommendations will be adjusted as needed to correspond with the latest research."
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Further reading

      1. Clinical Characteristics of Coronavirus Disease 2019 in China.
        N Engl J Med. 2020 Feb 28; https://doi.org/10.1056/NEJMoa2002032
        • Huang C.
        • et al.
        Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
        Lancet. 2020; 395: 497-506
        • Lu R.
        • Zhao X.
        • Li J.
        • Niu P.
        • Yang B.
        • Wu H.
        • et al.
        Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding.
        Lancet. 2020; 395: 565-574https://doi.org/10.1016/S0140-6736(20)30251-8
        • Hoffmann M.
        • et al.
        SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
        Cell. 2020 Mar 4; (pii: S0092-8674(20)30229-4)https://doi.org/10.1016/j.cell.2020.02.052
        • Ferrario C.M.
        • et al.
        Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
        Circulation. 2005 May 24; 111 (Epub 2005 May 16): 2605-2610
        • Kuba K.
        • Imai Y.
        • Rao S.
        • Gao H.
        • Guo F.
        • Guan B.
        • et al.
        A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
        Nature Medicine. August 2005; 11 (PMID 16007097): 875-879https://doi.org/10.1038/nm1267
        • Imai Y.
        • Kuba K.
        • Rao S.
        • Huan Y.
        • Guo F.
        • Guan B.
        • et al.
        Angiotensin-converting enzyme 2 protects from severe acute lung failure.
        Nature. July 2005; 436: 112-116
        • Zheng Y.
        • Ma Y.
        • Zhang J.
        • et al.
        COVID-19 and the cardiovascular system.
        Nat Rev Cardiol. 2020; https://doi.org/10.1038/s41569-020-0360-5